BioCentury
ARTICLE | Clinical News

PUR118: Phase Ib data

September 10, 2012 7:00 AM UTC

Top-line data from a 4-part, dose-ranging Phase Ib trial in healthy volunteers and COPD patients showed that inhaled PUR118 was well tolerated. On exploratory endpoints, Pulmatrix said that PUR118 showed a "favorable" impact on biomarkers of airway inflammation and mucociliary clearance velocity. Data were presented at the European Respiratory Society meeting in Vienna. Pulmatrix declined to disclose further details. ...